Aquestive Therapeutics, Inc. (AQST) Debt Components
- 2026-06-30: Debt, CurrentUSD $32.00K; Long-term Debt and Lease ObligationUSD $50.65M; Long-term DebtUSD $55.00M; Long-Term Debt, Maturity, Year OneUSD (m).
- 2026-03-31: Debt, CurrentUSD (m); Long-term Debt and Lease ObligationUSD $25.10M; Long-term DebtUSD $45.00M; Long-Term Debt, Maturity, Year OneUSD $14.54M.
- 2025-12-31: Debt, CurrentUSD $9.99M; Long-term Debt and Lease ObligationUSD $27.52M; Long-term DebtUSD (m); Long-Term Debt, Maturity, Year OneUSD (m).
- 2025-12-31: Debt, CurrentUSD (m); Long-term Debt and Lease ObligationUSD (m); Long-term DebtUSD $45.00M; Long-Term Debt, Maturity, Year OneUSD $9.54M.
Aquestive Therapeutics, Inc. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Debt, Current USD | Long-term Debt and Lease Obligation USD | Long-term Debt USD | Long-Term Debt, Maturity, Year One USD | Long-Term Debt, Maturity, Year Two USD | Long-Term Debt, Maturity, Year Three USD | Long-Term Debt, Maturity, Year Four USD | Long-Term Debt, Maturity, Year Five USD | Long-Term Debt, Maturity, Remainder of Fiscal Year USD | Long-Term Debt, Maturity, after Year Five USD | Debt Instrument, Face Amount USD | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $32.00K | $50.65M | $55.00M | (m) | (m) | (m) | (m) | $55.00M | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $25.10M | $45.00M | $14.54M | $20.93M | (m) | (m) | (m) | $9.54M | (m) | (m) | (m) |
| 2025-12-31 | $9.99M | $27.52M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | (m) | $45.00M | $9.54M | $14.54M | $20.93M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | (m) | $45.00M | $9.54M | $14.54M | $20.93M | (m) | (m) | $0.00 | (m) | (m) | (m) |
| 2025-06-30 | (m) | (m) | $45.00M | $9.54M | $14.54M | $20.93M | (m) | (m) | $0.00 | (m) | (m) | (m) |
| 2025-03-31 | (m) | (m) | $45.00M | $9.54M | $14.54M | $20.93M | (m) | (m) | $0.00 | (m) | (m) | (m) |
| 2024-12-31 | (m) | $32.50M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | (m) | $45.00M | $0.00 | $9.54M | $14.54M | $20.93M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | (m) | $45.00M | $0.00 | $9.54M | $14.54M | $20.93M | (m) | $0.00 | (m) | (m) | (m) |
| 2024-06-30 | (m) | (m) | $45.00M | $0.00 | $9.54M | $14.54M | $20.93M | (m) | $0.00 | (m) | (m) | (m) |
| 2024-03-31 | (m) | (m) | $45.00M | $0.00 | $9.54M | $14.54M | $20.93M | (m) | $0.00 | (m) | (m) | (m) |
| 2023-12-31 | (m) | $27.51M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | (m) | $45.00M | $0.00 | $0.00 | $9.54M | $14.54M | $20.93M | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | (m) | $38.98M | $19.49M | $10.32M | (m) | (m) | (m) | $9.17M | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | $38.98M | $19.49M | $10.32M | (m) | (m) | (m) | $9.17M | (m) | (m) | (m) |
| 2023-03-31 | (m) | (m) | $42.41M | $19.49M | $10.32M | (m) | (m) | (m) | $12.61M | (m) | (m) | (m) |
| 2022-12-31 | (m) | $33.45M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | (m) | $18.02M | $21.89M | $11.59M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | (m) | $51.50M | $18.02M | $21.89M | $11.59M | (m) | (m) | $0.00 | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | $51.50M | $18.02M | $21.89M | $11.59M | (m) | (m) | $0.00 | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | $51.50M | $18.02M | $21.89M | $11.59M | (m) | (m) | $0.00 | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | (m) | $0.00 | $18.02M | $21.89M | $11.59M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | $51.50M | $7.72M | $12.88M | $18.02M | $10.30M | (m) | $2.58M | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | $51.50M | $7.72M | $12.88M | $18.02M | $10.30M | (m) | $2.58M | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | $51.50M | $7.72M | $12.88M | $18.02M | $10.30M | (m) | $2.58M | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | $51.50M | $2.58M | $7.72M | $12.88M | $18.02M | $10.30M | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | $70.00M | $3.50M | $10.50M | $17.50M | $24.50M | $14.00M | $0.00 | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | $70.00M | $3.50M | $10.50M | $17.50M | $24.50M | $14.00M | $0.00 | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | $70.00M | $3.50M | $10.50M | $17.50M | $24.50M | $14.00M | $0.00 | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | $70.00M | $0.00 | $3.50M | $10.50M | $17.50M | (m) | (m) | $38.50M | (m) | (m) |
| 2019-09-30 | (m) | (m) | $70.00M | (m) | $0.00 | $3.50M | $10.50M | $17.50M | $0.00 | (m) | (m) | $0.00 |
| 2019-07-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $70.00M | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $2.02M |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $2.41M |
| 2018-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $2.80M |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $3.20M |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $3.57M |
| 2017-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $4.49M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |